Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 10Osteosarcoma 4Uterine Neoplasms 1Neoplasms, Connective and Soft Tissue 1Liposarcoma 1Drug-Related Side Effects and Adverse Reactions 1Chordoma 1

Interventions

Nivolumab 6Imatinib Mesylate 4Ipilimumab 3Cetuximab 3pembrolizumab 2palbociclib 2Specimen Handling 2Radiotherapy 2Radiosurgery 2Protons 2Proton Therapy 2Pemetrexed 2Magnetic Resonance Spectroscopy 2Cyclophosphamide 2tazemetostat 1spartalizumab 1relatlimab 1nilotinib 1camrelizumab 1avelumab 1atezolizumab 1apatinib 1Zoledronic Acid 1X-Rays 1Tiragolumab 1Thiotepa 1Surveys and Questionnaires 1Radiotherapy, Intensity-Modulated 1Radiation 1Photochemotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Chordoma × camrelizumab × Sarcoma × Clear all
NCT06140732 2023-11-20

Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma

Xuanwu Hospital, Beijing

Phase 2 Unknown
30 enrolled
Sarcoma

Chordoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡